318 drugs, such as atorvastatin, risuvar and entecavir, were greatly reduced in price

Source: procurement platform of Guangzhou Pharmaceutical Group ▍ sorting out: saibailan Banxia, February 20, Guangzhou Pharmaceutical Group procurement platform issued the notice of Guangzhou Medical Insurance Service Center on completing the declaration of the lowest price of drugs negotiated by the third batch of medical insurance groups in China According to the notice, the third batch of negotiated drug-related manufacturers shall declare the latest national minimum transaction price of negotiated products through the purchase platform of Guangzhou Pharmaceutical Group from February 20 to February 23, involving 318 drugs in total According to the notice, the national minimum price refers to the lowest value of the national actual transaction price (the price of signing the drug purchase and sale contract or the invoice price distributed to the medical institution) produced and being implemented as of the date of declaration Failure to submit on time or declare a price of zero shall be deemed as a waiver of this negotiation qualification In order to correctly submit the national minimum price, the false price shall be handled according to the trial measures In the third batch of negotiated varieties list, there are several varieties in the 4 + 7 belt purchase list, such as atorvastatin, rosuvastatin, clopidogrel, irbesartan, entecavir, imatinib, etc from the perspective of the manufacturers of these varieties, there are no lack of 4 + 7 winning and losing enterprises It is reported that compared with the lowest purchase price of the same kind of drugs in these pilot cities last year, the average price of the selected 25 drugs purchased in 4 + 7 with volume will decrease by 52%, and the highest decrease will be about 96% On February 20, the procurement platform of Guangzhou Pharmaceutical Group issued the notice of Guangzhou Medical Insurance Service Center on the implementation of the procurement bidding work of Guangzhou medical institution Pharmaceutical Group According to the notice, the candidate varieties for commercial bid evaluation shall be quoted and decrypted through the procurement platform of Guangzhou Pharmaceutical Group within the specified time on February 25 Drugs are divided according to the quality level and bidding in the same group according to the grouping results The price comparison in the same group is calculated according to the national price comparison rules The enterprise shall confirm the price after the difference within the specified time The final bidding results in one variety to be traded and one candidate variety As a pioneer of GPO procurement, the price reduction of the first three batches of volume procurement in Shanghai has been admirable, with an average decrease of 64% in the first batch, 53% in the second batch and 54% in the third batch It can be predicted that GPO in Guangzhou, price reduction is also a choice that pharmaceutical companies have to make It remains to be seen to what extent the final price reduction will be achieved Example of differential price calculation: attached: the third batch of negotiated varieties of medical insurance group original title: 318 drug price reduction opened! Atorvald, risuva, entecavir